Stock Events

Stock Events

PolyPeptide Group 

CHF44.00
13
+CHF0.15+0.34%Friday 16:30

Statistics

Day High
44
Day Low
42.8
52W High
44.15
52W Low
41
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 13Expected
Q2 2026
0.07
0.13
0.19
0.26
Expected EPS
0.0650745788
Actual EPS
0.2556919646578

Financials

-5.45%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
363.03MRevenue
-19.8MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PPGNE.SW. It's not an investment recommendation.
Kuehne + Nagel International
3
KNIN.SW
Idorsia
3
IDIA.SW
Implenia
3
IMPN.SW
Apple
2
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bank of China
BACHF
Mkt Cap209.44B
Bachem Holding AG specializes in peptide technology, directly competing in the same sector as PolyPeptide.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. develops peptide therapeutics among other biotech solutions, overlapping with PolyPeptide's market.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company, through its acquisition of Prevail Therapeutics, competes in peptide drug development.
Novartis
NVS
Mkt Cap303.67B
Novartis AG engages in significant research in peptide-based drugs, competing for similar market share.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has investments in peptide research and drug development, positioning it as a competitor.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG develops peptide therapeutics, directly competing with PolyPeptide in the biopharmaceutical field.
Sanofi
SNY
Mkt Cap106.24B
Sanofi SA focuses on peptide drug solutions among its diverse biopharmaceutical products, competing with PolyPeptide.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. has a strong focus on innovative drug development including peptides, competing in the same arena.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline plc invests in peptide-based drug development, making it a competitor in this specialized field.

About

Operating globally, PolyPeptide Group AG functions as a prominent contract development and manufacturing organization (CDMO). The company specializes in producing both proprietary and generic GMP-certified peptides, which are supplied to pharmaceutical and biotechnology firms. These crucial components are integrated into approved pharmaceutical products, drugs in various stages of clinical development, and generic medications. PolyPeptide Group also handles the manufacturing of bespoke research-grade peptides and is engaged in the development of neoantigen peptides designed to advance personalized cancer therapies. Its services further encompass the production of peptides for commercially available peptide therapeutics, as well as the creation of peptide-based generics for both human and animal health sectors, alongside peptides for the cosmetics industry. Additionally, the company offers vital regulatory affairs assistance. Established in 1952, PolyPeptide Group AG maintains its corporate headquarters in Zug, Switzerland, and operates as a subsidiary of Draupnir Holding B.V.
Show More
CEO
Juan Jose Gonzalez
Employees
1469
Country
Switzerland
ISIN
CH1593449767

Listings

F
DE
8H0.F
STU
DE
8H0.STU
MU
DE
8H0.MU
LSE
GB
0AAJ.LSE

0 Comments

Share your thoughts

FAQs

What is PolyPeptide Group stock price today?▼
The current price of PPGNE.SW is CHF44.00 CHF — it has increased by +0.34% in the past 24 hours. Watch PolyPeptide Group stock price performance more closely on the chart.
What is PolyPeptide Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on SIX Swiss Exchange exchange PolyPeptide Group stocks are traded under the ticker PPGNE.SW.
When is the next PolyPeptide Group earnings date?▼
PolyPeptide Group is going to release the next earnings report on March 9, 2027.
What were PolyPeptide Group earnings last quarter?▼
PPGNE.SW earnings for the last quarter are 0.26 CHF per share, whereas the estimation was 0.07 CHF resulting in a +292.92% surprise. The estimated earnings for the next quarter are N/A CHF per share.
What is PolyPeptide Group revenue for the last year?▼
PolyPeptide Group revenue for the last year amounts to 363.03M CHF.
What is PolyPeptide Group net income for the last year?▼
PPGNE.SW net income for the last year is -19.8M CHF.
How many employees does PolyPeptide Group have?▼
As of November 7, 2026, the company has 1,469 employees.
In which sector is PolyPeptide Group located?▼
PolyPeptide Group operates in the Health & Wellness sector.
When did PolyPeptide Group complete a stock split?▼
PolyPeptide Group has not had any recent stock splits.
Where is PolyPeptide Group headquartered?▼
PolyPeptide Group is headquartered in Baar, Switzerland.